Zealand Pharma Past Earnings Performance
Past criteria checks 0/6
Zealand Pharma's earnings have been declining at an average annual rate of -31.7%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been growing at an average rate of 20.9% per year.
Key information
-31.7%
Earnings growth rate
-27.7%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 20.9% |
| Return on equity | -44.2% |
| Net Margin | -205.3% |
| Next Earnings Update | 16 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Zealand Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 343 | -704 | 216 | 0 |
| 30 Sep 23 | 343 | -760 | 205 | 654 |
| 30 Jun 23 | 92 | -986 | 215 | 602 |
| 31 Mar 23 | 107 | -1,064 | 241 | 612 |
| 31 Dec 22 | 104 | -966 | 258 | 0 |
| 30 Sep 22 | 93 | -855 | 273 | 612 |
| 30 Jun 22 | 104 | -845 | 286 | 606 |
| 31 Mar 22 | 114 | -608 | 231 | 446 |
| 31 Dec 21 | 109 | -755 | 298 | 582 |
| 30 Sep 21 | 158 | -925 | 416 | 595 |
| 30 Jun 21 | 161 | -1,012 | 480 | 595 |
| 31 Mar 21 | 347 | -909 | 575 | 574 |
| 31 Dec 20 | 192 | -669 | 222 | 596 |
| 30 Sep 20 | 301 | -660 | 300 | 612 |
| 30 Jun 20 | 255 | -545 | 178 | 596 |
| 31 Mar 20 | 54 | -624 | 79 | 605 |
| 31 Dec 19 | 41 | -572 | 68 | 561 |
| 30 Sep 19 | 43 | -508 | 68 | 522 |
| 30 Jun 19 | 33 | 524 | 62 | 486 |
| 31 Mar 19 | 28 | 551 | 50 | 471 |
| 31 Dec 18 | 38 | 581 | 44 | 438 |
| 30 Sep 18 | 35 | 601 | 49 | 394 |
| 30 Jun 18 | 74 | -361 | 47 | 375 |
| 31 Mar 18 | 68 | -346 | 52 | 347 |
| 31 Dec 17 | 136 | -274 | 47 | 324 |
| 30 Sep 17 | 306 | -112 | 58 | 293 |
| 30 Jun 17 | 307 | -100 | 55 | 274 |
| 31 Mar 17 | 306 | -102 | 61 | 259 |
| 31 Dec 16 | 231 | -157 | 59 | 262 |
| 30 Sep 16 | 221 | -138 | 51 | 243 |
| 30 Jun 16 | 189 | -158 | 55 | 237 |
| 31 Mar 16 | 188 | -139 | 48 | 224 |
| 31 Dec 15 | 188 | -114 | 48 | 212 |
| 30 Sep 15 | 27 | -246 | 48 | 217 |
| 30 Jun 15 | 78 | -178 | 44 | 212 |
| 31 Mar 15 | 75 | -147 | 39 | 195 |
| 31 Dec 14 | 154 | -65 | 40 | 180 |
| 30 Sep 14 | 151 | -47 | 31 | 160 |
| 30 Jun 14 | 95 | -98 | 33 | 151 |
| 31 Mar 14 | 92 | -97 | 35 | 147 |
| 31 Dec 13 | 7 | -184 | 34 | 164 |
| 30 Sep 13 | 3 | -191 | 34 | 177 |
| 30 Jun 13 | 38 | -157 | 33 | 186 |
Quality Earnings: 22Z is currently unprofitable.
Growing Profit Margin: 22Z is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 22Z is unprofitable, and losses have increased over the past 5 years at a rate of 31.7% per year.
Accelerating Growth: Unable to compare 22Z's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 22Z is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).
Return on Equity
High ROE: 22Z has a negative Return on Equity (-44.18%), as it is currently unprofitable.